Based in Cambridge, UK, we are making better medicines by continually improving the best antibody technologiesLearn more
Our unique technologies drive our rapid development of effective, human antibodies across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.View our pipeline
Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.View our vacancies
Kymab congratulates Sir Greg Winter on his Nobel prize and thanks him for his major contribution to making the therapeutic use of human a...
Forbes magazine recognises Kymab's work is 'exciting the big and little guys' and places the company in a select group of UK 'Unicorns'
Positive data in Phase I trial of KY1005 will lead to Phase II studies in atopic dermatitis, with additional plans to run studies in othe...
First study to combine an anti-ICOS antibody with an anti-PD-L1 antibody in Phase I/II studies will evaluate Kymab's lead investigational...
1 Dec 2018 - 4 Dec 2018 | San Diego Convention Center, San Diego, California, USA
View event details